NextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024
NextCure, Inc. (NASDAQ:NXTC) and LigaChem Biosciences, Inc.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Squadron Capital Management William Blank | 265,000 | $2,830,200 | +12% | 1.04% |
| 2. | Ikarian Capital Neil Shahrestani | 238,303 | $2,506,947 | 0.2% | |
| 3. | SilverArc Capital Devesh Gandhi | 176,057 | $1,880,289 | 0.19% | |
| 4. | Opaleye Management James A. Silverman | 141,181 | $1,507,813 | 0.2% | |
| 5. | Exome Asset Management Samuel Isaly | 115,500 | $1,215,060 | -30% | 0.63% |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.00 | 1,600 | $8,000.00 | 393,266 | 2026-07-29 | Filing | |
| $5.00 | 1,810 | $9,050.00 | 391,666 | 2026-07-29 | Filing | |
| $4.95 | 6,400 | $31,677.44 | 389,856 | 2026-07-28 | Filing | |
| $5.00 | 7,798 | $38,985.32 | 383,456 | 2026-07-27 | Filing | |
| $36.75 | 150,000 | $5,512,500.00 | 2,671,856 | 2019-11-15 | Filing |